Evidence map›Paper›PMID 35133817›Full record

ArticleThe Journal of organic chemistry2022

An Optimized Synthesis of Fmoc-l-Homopropargylglycine-OH.

Daniel Polyak, Isaac J Krauss

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of organic chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel PolyakDepartment of Chemistry, Brandeis University, MS 015, Waltham, Massachusetts 02454-9110, United States.
Isaac J KraussDepartment of Chemistry, Brandeis University, MS 015, Waltham, Massachusetts 02454-9110, United States.ORCID 0000-0003-0984-4085

Funding

Rational and Combinatorial Design of Immunogens to Elicit 2G12-like AntibodiesR01AI090745 · NIAID · BRANDEIS UNIVERSITY · PI KRAUSS, ISAAC JONATHAN · 2010 to 2022
$3.9M
Design of Immunogens to Elicit PGT122 like AntibodiesR01AI113737 · NIAID · BRANDEIS UNIVERSITY · PI KRAUSS, ISAAC JONATHAN · 2014 to 2018
$2.2M
Glycopeptide evolution targeting antibodies of the PGT128 lineage.R56AI090745 · NIAID · BRANDEIS UNIVERSITY · PI KRAUSS, ISAAC JONATHAN · 2017 to 2017
$523k
Directed Evolution of Zika EDE GlycoantigensR21AI140030 · NIAID · BRANDEIS UNIVERSITY · PI KRAUSS, ISAAC JONATHAN · 2018 to 2019
$453k
NIAID NIH HHS R01 AI090745NIAID NIH HHS R01 AI113737NIAID NIH HHS R21 AI140030NIAID NIH HHS R56 AI090745
6 · The paper itself

Abstract

An efficient multigram synthesis of alkynyl amino acid Fmoc-l-homopropargylglycine-OH is described. A double Boc protection is optimized for high material throughput, and the key Seyferth-Gilbert homologation is optimized to avoid racemization. Eighteen grams of the enantiopure (>98% ee) noncanonical amino acid was readily generated for use in solid phase synthesis to make peptides that can be functionalized by copper-assisted alkyne-azide cycloaddition.

Indexed as

AlkynesSolid-Phase Synthesis TechniquesAmino AcidsAzidesFluorenesGlycineAlkynesAmino AcidsAzidesFluorenesGlycinehomopropargylglycine

Identifiers

PMID35133817
PMCPMC11960788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.